Álvarez-Román, Maria Teresa, Ignacio Cuervo-Arango, Rafael Pérez-Santamarina, José Luís Poveda, José Antonio Romero, Amparo Santamaría, José Luís Trillo-Mata, Marina Tort, and Xavier Badia. “Determining the Value Contribution of Emicizumab (Hemlibra®) for the Prophylaxis of Haemophilia A With Inhibitors in Spain by Multi-Criteria Decision Analysis”. Global and Regional Health Technology Assessment 6, no. 1 (October 8, 2019). Accessed March 28, 2024. https://journals.aboutscience.eu/index.php/grhta/article/view/452.